Cancer Treatment at GoBroad Healthcare Group, China
China's leading research hospital network for blood cancers and solid tumours, with CAR-T therapy, targeted drug access, and multidisciplinary cancer care.
Why International Patients Choose GoBroad for Cancer Treatments in China
Bumrungrad is a recognised global leader in orthopaedics with internationally trained specialists across orthopaedic surgery, sports medicine, neurology, oncology, and rehabilitation.
- 90%+ CAR-T remission rate for relapsed B-cell leukaemia, published in Blood and Nature Medicine.
- Thousands of CAR-T treatments completed.
- Thousands of CAR-T treatments completed.
- Written cost estimate provided before travel, covering CAR-T, targeted therapy, or solid tumour surgery.
- 1,500+ diagnostic tests at the GoBroad Precision Diagnostics Centre using NGS and flow cytometry.
Cancer Treatment Technology Used at GoBroad in Beijing and Shanghai
- Next-generation sequencing (NGS)
- CAR-T manufacturing platform
- Siemens 3.0T MRI
- PET-CT imaging
- Flow cytometry analysis
- Mass spectrometry diagnostics
Cancer Treatments for International Patients at GoBroad Hospitals in China
Each cancer treatment plan is built from individual molecular profiling, disease staging, and prior treatment history.
CAR-T Cell Therapy
Re-engineers your own immune cells to find and destroy blood cancer cells when standard therapies have stopped working.
Inquire
Chemotherapy
Targets and destroys rapidly dividing cancer cells in the blood, bone marrow, and lymphatic system.
Inquire
Targeted therapy
Immunotherapy
Uses the immune system or engineered antibodies to identify and destroy blood cancer cells.
Inquire
Care Journey for International Patients
Your cancer treatment journey made simple and stress-free in 5 easy steps
-
1
Online inquiry & medical files upload Share your medical reports for review. It takes less than a minute.
-
2
Doctor review & treatment plan Within 24hrs you will receive treatment options & a preliminary plan before travel.
-
3
Travel coordination We arrange your visa, flights, and accommodation.
-
4
Treatment phase Full care under a dedicated case manager.
-
5
Start your treatment Begin treatment with full support from our care team.
Frequently Asked Questions
Have a question? Our support team is here to guide you through each step of your treatment journey with personal care and attention.How do I contact the international patient support team for cancer treatment at GoBroad?
Cancer treatment appointments, cost estimates, and treatment planning at GoBroad Healthcare Group in China are coordinated through the International Patient Care team at My1Health, which supports international patients before, during, and after travel.
- WhatsApp: +1 718 550 0880
- Telephone: +1 718 550 0880
- Email: [email protected]
The team arranges online video consultations with cancer specialists, remote review of your diagnosis and scans, written cost estimates, medical visa documentation, and full treatment coordination.
How long will I need to stay in China for cancer treatment?
Length of stay depends on the cancer type and treatment approach. As a guide:
- CAR-T cell therapy requires several weeks of inpatient stay, covering cell collection, manufacturing, infusion, and initial monitoring.
- Chemotherapy cycles are usually administered over several days per cycle with gaps between; some patients manage part of their treatment remotely after returning home.
- Solid tumour surgery requires an inpatient stay that varies by procedure, followed by a monitored recovery period before discharge.
- Radiotherapy courses run over several weeks of daily or near-daily sessions.
GoBroad's international patient coordinator prepares a personalised treatment itinerary before you travel, giving you a clear timeline before you commit to coming.
How quickly can international patients access newly approved targeted drugs at GoBroad?
GoBroad Healthcare Group provides access to newly approved targeted drugs in China shortly after NMPA (National Medical Products Administration) regulatory approval.
In one documented case, an international patient from Russia with KRAS G12C-mutated advanced lung cancer received Furazercib, the first Chinese-developed KRAS G12C targeted drug, just 10 days after its NMPA approval in August 2024, making him among the first patients in the world to receive it.
For international patients who have failed multiple lines of therapy or cannot access specific drugs in their home country, GoBroad's position as a research hospital embedded in China's biomedical innovation system gives direct, rapid access to newly approved treatments.
Is CAR-T cell therapy available for solid tumour patients at GoBroad?
Yes, GoBroad is actively expanding CAR-T therapy beyond blood cancers into solid tumours through investigator-initiated trials.
The Claudin18.2 CAR-T programme targets gastric and gastrointestinal cancers, and GoBroad's research teams are actively enrolling patients for trials exploring CAR-T for digestive tract tumours and other solid tumour types.
For blood cancers, commercial CAR-T and IIT protocols are both available, including single-target and dual-target options covering CD19, CD22, BCMA, GPRC5D, CD7, and CD5.
Several thousand CAR-T treatments have been completed across GoBroad's hospitals.
What cancers does GoBroad Healthcare Group treat for international patients?
GoBroad Healthcare Group treats both blood cancers and solid tumours, covering the full range of haematological malignancies and major solid tumour types.
Blood cancers treated include
- Leukaemia (ALL, AML, CML, CLL)
- Lymphoma (Hodgkin and non-Hodgkin)
- Multiple myeloma
Solid tumours treated include:
- Lung cancer
- Gastric cancer
- Colorectal cancer
- Hepatocellular carcinoma
- Pancreatic cancer
- Cholangiocarcinoma
- Osteosarcoma
- Melanoma
- Urological cancers
For patients with relapsed or refractory disease who have exhausted standard options, GoBroad's CAR-T therapy, investigator-initiated trials, and combination strategies offer treatments that are not available in most countries.
What makes cancer treatment in China at GoBroad different from treatment at home or in Europe?
GoBroad Healthcare Group gives international cancer patients access to three things that are difficult to find together elsewhere:
- Investigator-initiated CAR-T trials for novel targets not yet commercially available
- Rapid access to newly approved targeted drugs approved by China's NMPA
- Combination transplant and CAR-T strategy for relapsed or refractory cases
Cancer treatment costs in China are lower than equivalent treatment in the US or Germany, providing same level of clinical credibility as leading Western centres at a fraction of the cost.
Will GoBroad review my existing diagnosis and scans before I travel to China?
Yes. GoBroad's international patient team arranges a remote review of your existing diagnosis, pathology reports, imaging results, and molecular profiling data before you travel.
An online consultation with the relevant cancer specialist is scheduled based on your case, and a written cost estimate is prepared so you understand the financial expectations before any commitment is required.
This review is available for all cancer types treated at GoBroad, including both blood cancers and solid tumours.
